Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults

Leukemia volume 30, pages 1177–1180 (2016)Cite this article

Subjects

Among cancer patients, adolescents and young adults (AYA; ages 15–39 years) are considered a high-risk group because improvement in survival over the past decades generally lags behind the younger and older patients.1 Unlike acute lymphoblastic leukemia, data on acute myelogenous leukemia (AML) in AYA are limited and generally derived from clinical trials. The latter are mostly conducted in academic centers.2, 3 It is unclear whether the type of treatment facility, academic versus community centers, influences the clinical outcome independent of disease biology and sociodemographic factors. Our study used the National Cancer Data Base (NCDB), a joint program of the American College of Surgeon’s Commission on Cancer (CoC) and the American Cancer Society, to address this question.

NCDB is a nationwide oncology database sourced from hospital registry data covering 70% of the US cancer population. The data elements are collected prospectively from CoC-accredited program cancer registries using nationally standardized data item and coding definitions. These include patient characteristics, cancer staging and tumor histological characteristics, type and timing of first course of treatment administered, and overall survival. The PUF is a Health Insurance Portability and Accountability Act-compliant data file that contains de-identified patient level data.4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Shaw PH, Reed DR, Yeager N, Zebrack B, Castellino SM, Bleyer A . Adolescent and young adult (AYA) oncology in the United States: a specialty in its late adolescence. J Pediatr Hematol Oncol 2015; 37: 161–169.

    Article  PubMed  Google Scholar 

  2. Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer 2013; 119: 4162–4169.

    Article  PubMed  Google Scholar 

  3. Woods WG, Franklin AR, Alonzo TA, Gerbing RB, Donohue KA, Othus M et al. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer 2013; 119: 4170–4179.

    Article  CAS  PubMed  Google Scholar 

  4. National Cancer Data Base. Available from https://www.facs.org/quality%20programs/cancer/ncdb (accessed date 24 March 2015).

  5. Schemper M, Wakounig S, Heinze G . The estimation of average hazard ratios by weighted Cox regression. Stat Med 2009; 28: 2473–2489.

    Article  PubMed  Google Scholar 

  6. Li KH, Meng XL, Raghunathan TE, Rubin DB . Significance levels from repeated P-values with multiply-imputed data. Stat Sinica 1991; 1: 65–92.

    Google Scholar 

  7. Rubin DB, Schenker N . Multiple imputation for interval estimation from simple random samples with ignorable nonresponse. J Am Stat Assoc 1986; 81: 366–374.

    Article  Google Scholar 

  8. Stiller CA, Benjamin S, Cartwright RA, Clough JV, Gorst DW, Kroll ME et al. Patterns of care and survival for adolescents and young adults with acute leukaemia—a population-based study. Br J Cancer 1999; 79: 658–665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37: 1004–1009.

    Article  CAS  PubMed  Google Scholar 

  10. Grimwade D, Burnett AK . Getting to the heart of improving outcomes for patients with acute promyelocytic leukemia. Oncology 2012; 26: 647–649.

    PubMed  Google Scholar 

  11. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253.

    CAS  PubMed  Google Scholar 

  12. All-trans retinoic acid (systemic tretinoin): Drug Information. Available from http://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-drug-information?source=search_result&search=vesanoid&selectedTitle=1%7E96#F230429 (accessed date 26 June 2015).

Download references

Acknowledgements

This study was funded by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and the Division of Hematology. RSG is a Kern Health Care Delivery Scholar.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    R S Go & A Al-Kali

  2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA

    R S Go, N D Shah & E B Habermann

  3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    A C Bartley

Authors
  1. R S Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A C Bartley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Al-Kali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N D Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E B Habermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R S Go.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Go, R., Bartley, A., Al-Kali, A. et al. Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults. Leukemia 30, 1177–1180 (2016). https://doi.org/10.1038/leu.2015.239

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.239

Search

Advanced search

Quick links